Estrella Immunopharma Inc.
ESLA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ESLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ESLA
Estrella Immunopharma Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies, currently advancing its lead candidate EB103 through a Phase I/II clinical trial (STARLIGHT-1) while facing significant financial challenges and a going concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Estrella Immunopharma Inc..
Similar companies
Estrella Immunopharma Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies, currently advancing its lead candidate EB103 through a Phase I/II clinical trial (STARLIGHT-1) while facing significant financial challenges and a going concern risk.
- Lead product candidate EB103 is being evaluated in the Phase I/II STARLIGHT-1 clinical trial; Phase I dosing was completed in November 2025 and the first Phase II patient was dosed in January 2026 [sec_mda · as of 2026-05-18].
- As of June 30, 2026, the company had cash and equivalents of $0.1M, a net loss of $2.3M for the quarter, and an accumulated deficit of approximately $41.6M [sec_mda · as of 2026-08-13].
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-05-18].
- Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing [sec_mda · as of 2026-08-13].
What works
- The company has advanced its lead candidate EB103 into Phase II of the STARLIGHT-1 trial, with the first Phase II patient dosed in January 2026 [sec_mda · as of 2026-05-18].
- Estrella has secured financing through a private placement (May–September 2025) and a Registered Direct Offering (January 2026) that provided net proceeds of approximately $7.2 million [sec_mda · as of 2026-05-18].
What to weigh
- As of June 30, 2026, the company had only $0.1M in cash and equivalents and a shareholders' equity of -$7.4M, indicating severe liquidity constraints [sec_mda · as of 2026-08-13].
- The company has an accumulated deficit of approximately $41.6M as of June 30, 2026, and has never generated product revenue [sec_mda · as of 2026-08-13].
- Management has identified substantial doubt about the company's ability to continue as a going concern, and the independent auditor has included an explanatory paragraph in its report [sec_mda · as of 2026-08-13].
- The company faces significant contractual obligations under the STARLIGHT-1 trial, with total non-refundable net fees of $33.0 million to Eureka, of which approximately $17.8 million had been incurred as of March 31, 2026 [sec_mda · as of 2026-05-18].
From the filings
Quoted directly from source documents.
Phase I dosing completed and Phase II patient dosed in STARLIGHT-1 trial
“In November 2025, the Company announced the completion of Phase I dosing in the STARLIGHT-1 clinical trial of EB103, our lead product candidate. On January 9, 2026, one Phase II patient was dosed in the STARLIGHT-1 clinical trial, representing the tenth patient dosed in total.”
SEC MD&A · May 18, 2026
Accumulated deficit of approximately $41.6 million as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of approximately $41.6 million.”
SEC MD&A · August 13, 2026
Going concern and substantial doubt about ability to continue
“Our recurring losses from operations, accumulated deficit, and need for additional financing to fund future operations, raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has substantial doubt about the company's ability to continue as a going concern due to recurring losses and need for additional financing [sec_mda · as of 2026-08-13].
- Cash runway uncertainty — As of June 30, 2026, cash and equivalents were only $0.1M, with no product revenue and significant ongoing trial costs [sec_mda · as of 2026-08-13].
- No approved products or revenue — The company has no product candidates approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-05-18].
- Large contractual obligations — Total non-refundable net fees of $33.0M are owed to Eureka under the STARLIGHT-1 trial SOW, with $17.8M incurred as of March 31, 2026 [sec_mda · as of 2026-05-18].
What to watch
- Progress of the STARLIGHT-1 Phase II trial enrollment and any interim data readouts [sec_mda · as of 2026-05-18].
- Ability to raise additional capital given the low cash balance and going concern status [sec_mda · as of 2026-08-13].
- Any updates on the company's ability to meet its contractual milestone payments to Eureka [sec_mda · as of 2026-05-18].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Estrella Immunopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Estrella Immunopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.1 months
OCF -$2M · Net income -$2M
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$5.9M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 4,099,000 | $4.3M |
| vanguard capital management llc | 764,938 | $811K |
| wells fargo & company/mn | 264,388 | $280K |
| geode capital management, llc | 157,485 | $167K |
| vanguard fiduciary trust co | 64,921 | $69K |
| renaissance technologies llc | 62,795 | $67K |
| state street corp | 43,252 | $46K |
| blackrock, inc. | 39,890 | $42K |
| northern trust corp | 19,624 | $21K |
| ubs group ag | 15,079 | $16K |
Showing top 10 of 15 institutional holders of Estrella Immunopharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 3.8%
- Days to cover
- 11.8
- Shares short
- 626,324
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ESLA short interestFrequently asked questions
What is the AI investment thesis for Estrella Immunopharma Inc.?
Estrella Immunopharma Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies, currently advancing its lead candidate EB103 through a Phase I/II clinical trial (STARLIGHT-1) while facing significant financial challenges and a going concern risk.
What is Estrella Immunopharma Inc.'s lead drug candidate?
Estrella Immunopharma Inc.'s most advanced tracked candidate is eb103 (Phase 1/Phase 2) for B-Cell Non-Hodgkin's Lymphoma (NHL).
Who is the CEO of Estrella Immunopharma Inc.?
Dr. Cheng Liu Ph.D. is the chief executive officer of Estrella Immunopharma Inc. (ESLA).
Where is Estrella Immunopharma Inc. headquartered?
Estrella Immunopharma Inc. (ESLA) is headquartered in EmeryVille, CA, United States.
What therapeutic areas does Estrella Immunopharma Inc. focus on?
Estrella Immunopharma Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.